School of International Pharmaceutical Business, China Pharmaceutical University, No. 639 Longmian Avenue, Jiangning District, Nanjing, 211198, Jiangsu, China.
China Center for Health Economic Research, Peking University, Beijing, China.
Qual Life Res. 2018 Nov;27(11):2799-2814. doi: 10.1007/s11136-018-1928-y. Epub 2018 Jul 6.
Over the past decade, a changing spectrum of disease has turned chronic non-communicable diseases (CNCDs) into the leading cause of death worldwide. During the 2015 in China, there were more than 6.6 million deaths from NCDs, which was the highest rate around the world. In the present study, we performed a systematic review to analyze the health-related quality of life (HRQoL) according to EQ-5D-3L instrument in patients with different kinds of CNCDs in China.
We searched PubMed, Embase, Web of Science, Cochrane Library, VIP, WanFang Data, and CNKI databases up to April 12, 2018, to identify all relevant studies that reported on HRQoL assessed by EQ-5D-3L instrument in Chinese patients with CNCDs. Expert consultation and hand-searching of reference lists from retrieved studies were employed to identify additional references. The variation of mean utility values, EQ-VAS score ranges, and responses for each EQ-5D dimension described in relevant studies were extracted.
A total of 5027 English-language articles and 618 Chinese-language articles were identified, among which 38 articles met full inclusion criteria. These 38 studies involved 18 kinds of CNCDs. In this review, the health utility for diabetes mellitus ranged from 0.79 to 0.94 (EQ-5D VAS scores from 61.5 to 78.6), hypertension from 0.78 to 0.93 (70.1-77.4), coronary heart disease from 0.75 to 0.90 (71.0-77.0), chronic obstructive pulmonary disease from 0.64 to 0.80 (55.0-67.0), epilepsy from 0.83 to 0.87 (78.3-79.6), cerebral infarction from 0.51 to 0.75 (49.7-79.0), while children cerebral palsy was 0.44 (27.3).
EQ-5D-3L is widely used in studies of HRQoL associated with CNCDs in China. Our results suggest that many factors may influence the measurement results of health utilities, including age, gender, sample source, comorbidities, rural/urban, and EQ-5D-3L value sets.
在过去的十年中，疾病谱的变化使慢性非传染性疾病（CNCDs）成为全球死亡的主要原因。2015 年在中国，有超过 660 万人死于非传染性疾病，这是全球最高的死亡率。在本研究中，我们进行了系统评价，根据 EQ-5D-3L 工具分析了中国不同类型 CNCD 患者的健康相关生活质量（HRQoL）。
我们检索了 PubMed、Embase、Web of Science、Cochrane Library、VIP、WanFang Data 和 CNKI 数据库，截至 2018 年 4 月 12 日，以确定所有报告中国 CNCD 患者使用 EQ-5D-3L 工具评估的 HRQoL 的相关研究。专家咨询和从检索到的研究中手动搜索参考文献，以确定其他参考文献。提取了相关研究中描述的每个 EQ-5D 维度的平均效用值、EQ-VAS 评分范围和反应的变化。
共确定了 5027 篇英文文章和 618 篇中文文章，其中 38 篇符合完全纳入标准。这些 38 项研究涉及 18 种 CNCD。在本综述中，糖尿病的健康效用值范围为 0.79 至 0.94（EQ-5D VAS 评分范围为 61.5 至 78.6），高血压为 0.78 至 0.93（70.1 至 77.4），冠心病为 0.75 至 0.90（71.0 至 77.0），慢性阻塞性肺疾病为 0.64 至 0.80（55.0 至 67.0），癫痫为 0.83 至 0.87（78.3 至 79.6），脑梗死为 0.51 至 0.75（49.7 至 79.0），而儿童脑瘫为 0.44（27.3）。
EQ-5D-3L 在中国广泛应用于与 CNCD 相关的 HRQoL 研究。我们的结果表明，许多因素可能影响健康效用的测量结果，包括年龄、性别、样本来源、合并症、城乡和 EQ-5D-3L 值集。
